Scientists test Triple-Threat treatment to shrink tumors before surgery
NCT ID NCT06461910
Summary
This study is testing a new combination treatment for people with stage III stomach or gastroesophageal junction cancer. The goal is to see if giving immunotherapy (Serplulimab), an immune-boosting drug (thymalfasin), and standard chemotherapy (SOX) before surgery can shrink tumors more effectively. Researchers will enroll 30 patients to measure how many have no cancer left in their tissue after this pre-surgery treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.